ACADIA Pharmaceuticals Inc (ACAD)

31.02
0.41 1.30
NASDAQ : Health Care
Prev Close 31.43
Open 31.48
Day Low/High 30.93 / 31.65
52 Wk Low/High 16.64 / 50.40
Volume 1.29M
Avg Volume 2.64M
Exchange NASDAQ
Shares Outstanding 121.11M
Market Cap 3.80B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Biotechs Screaming 'Takeover Target'

3 Biotechs Screaming 'Takeover Target'

M&A activity should perk up substantially in the small and mid-cap space this year.

Hey, What About the Transports?

They were red today and no one seems to care.

ACADIA Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference On January 10, 2017

ACADIA Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference On January 10, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Starbucks, Allergan, Amazon: Doug Kass' Views

Starbucks, Allergan, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'

Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study

Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study

Shares of Acadia jumped Tuesday after the bio-pharmaceutical company reported positive results for a drug used for Alzehimer's patients.

Acadia Pharma Takes Low Road to Justify Drug Push Into Alzheimer's Psychosis

Acadia Pharma Takes Low Road to Justify Drug Push Into Alzheimer's Psychosis

Acadia Pharmaceuticals uses scant, mediocre clinical data to justify moving Nuplazid into a late-stage clinical trial of Alzheimer's disease psychosis.

ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study Of Pimavanserin For Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study Of Pimavanserin For Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced positive top-line results from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis (AD Psychosis).

Allergan, Apple, Oakland Capital: Doug Kass' Views

Allergan, Apple, Oakland Capital: Doug Kass' Views

Doug Kass shares his thoughts on China and life insurers.

This Rally May Not Be Done, but It's Close

Friday’s action was enough for me to believe we’re near a real pullback.

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of CLARITY,...

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how Apple is still a short for him and that the market is still resistant.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of ADVANCE, a...

Acadia Shares Soar as Nuplazid Sales Easily Top Estimates

Acadia Shares Soar as Nuplazid Sales Easily Top Estimates

Acadia reported sales of its treatment for hallucinations associated with Parkinson's disease that more than doubled estimates in the third quarter.

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Here are Tuesday's top research calls, including downgrades for Bank of America, Depomed, Hertz and AT&T.

ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

ACADIA Pharmaceuticals Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia

ACADIA Pharmaceuticals Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of ENHANCE-1, a...

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

ACADIA Pharmaceuticals To Announce Third Quarter 2016 Financial Results On November 7, 2016

ACADIA Pharmaceuticals To Announce Third Quarter 2016 Financial Results On November 7, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Initiates Phase II Study Of Pimavanserin In Alzheimer's Disease Agitation

ACADIA Pharmaceuticals Initiates Phase II Study Of Pimavanserin In Alzheimer's Disease Agitation

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of SERENE, a...